For the time being, Madrigal Pharmaceuticals Inc.’s Rezdiffra (resmetirom) stands alone as the only U.S. FDA approved treatment for treating nonalcoholic steatohepatitis (NASH). But new and positive data from multiple companies show Madrigal may soon have company.
New and updated clinical data presented by biopharma firms at the European Association for the Study of the Liver Congress, including: Arrowhead, Takeda.
Sequana Medical NV has reported additional data on safety, survival and quality of life from its POSEIDON pivotal study in North America, evaluating its Alfapump device used in the treatment of patients with recurrent or refractory ascites caused by liver cirrhosis. The data were recently presented at the European Association for the Study of the Liver 2023 congress in Vienna.
New and updated clinical data presented by biopharma firms at the European Association for the Study of the Liver Congress, including: 89bio, Arrowhead, Mirum, Takeda, Vir.
New and updated preclinical and clinical data presented by biopharma firms at the EASL International Liver Congress, including: Antios, Ascletis, Chemomab, Immunocore, Ionis, Mirum.
New data confirming that Gilead Sciences Inc.’s Hepcludex (bulevirtide) effectively cures hepatitis delta virus (hepatitis D), one of the most severe viral infections of the liver, and favorable phase III results from Madrigal Pharmaceuticals Inc.’s nonalcoholic steatohepatitis (NASH) contender were among the highest-profile scientific announcements at the International Liver Congress (ILC) 2022.
New and updated preclinical and clinical data presented by biopharma firms at The International Liver Congress – The Annual Meeting of the European Association for the Study of the Liver, including: Arbutus, Arrowhead.
New and updated preclinical and clinical data presented by biopharma firms at The International Liver Congress – The Annual Meeting of the European Association for the Study of the Liver, including: Antios, Arrowhead, Assembly, Brii, Durect, Enanta, Mirum.
RSS
